Event info
Date:17 Nov
Time:08:30 - 11:00
Venue:Medicon Valley Alliance, Copenhagen
Contact person
Louise Fur Høier

Louise Fur Høier

Event Manager & PA to CEO

MVA Good Morning Meeting – Turning the black hole of data into a future goldmine

In this Good Morning Meeting, you will learn about successful strategies for recycling and future-proofing the valuable data assets generated in clinical studies.

The most common destiny of the data from clinical studies is to be condensed into a one-off report and then archived.

Meanwhile, lots of everyday activities throughout the organization can be accelerated by recycling this data. Collaborations and exits will also benefit if external partners can be offered immediate, yet strictly controlled, access to your data.

Date: Thursday 17th of November 2022
Time: 08:30 – 11:00 CET
Venue: Medicon Valley Alliance, Arne Jacobsens Allé 15, 2300 Copenhagen S, Denmark – Auditorium

SIGN UP

 

Program

08:30Networking, registration and light breakfast
9:00Welcome
David Munis Zepernick, Head of Member Engagement and Communication, Medicon Valley Alliance
9:05The challenges of limited data access in life-science organizations
Bertil Lindmark,CMO Galecto
9:15Being a step ahead by using data from past and ongoing studies
Bertil Lindmark,CMO Galecto
09:30Overcoming the external and internal bottlenecks in data access
Eva Kelty, CEO Capish
Strategies for future-proofing secure access to comprehensible data
Eva Kelty, CEO Capish
10:00Q&A
10:30Networking
11:00End of Good Morning Meeting

 

Speakers

 Bertil E. Lindmark, CMO Galecto.

Being MD, PhD as well as professor in Innovation and Entrepreneurship indicates Bertil’s exceptional combination of medical knowledge and skills in successful drug development.

Securing the approval of Astra Zeneca’s asthma medicine Symbicort and expanding the respiratory portfolio, Bertil was a change agent for the use of data in clinical development. His disruptive and influential methods include investigation of specific study combinations, innovative endpoint analysis, and early patient inclusion assessments.

In addition to being the medical expert and strategic lead for AstraZeneca’s Respiratory and Inflammation Therapy research division, Bertil has also served as CSO at Almirall, and CMO at ASLAN Pharmaceutical and eTheRNA Immunotherapies.

  
 Eva Kelty, CEO Capish

With a bachelor’s degree in statistics and more than 30 years of practical experience Eva is an expert in harmonizing, analyzing, and validating clinical data.

Alongside her present role as CEO, Eva is hands-on operational in projects aiming at making clients more self-sufficient in exploring their clinical data. From leading roles in CDC, Stricent, and Semcon, Eva has unique perspectives for creating balanced solutions where the client’s need of direct access to relevant data can coexist in synergy with effectively outsourced data analysis services.

 

 

Organized by
In collaboration with